The positive results achieved with DS mouse models, and more recently, in human pluripotent stem cells from patients with DS (DS-iPSCs), give reason to believe that DYRK1A suppression could be a viable strategy for improving cognition in DS patients [17]. This evidence concerns the gene DYRK1A and Dravet syndrome.